Exploring Quinovic Acid as a potential lung cancer therapy: Insights from network pharmacology and molecular docking
DOI:
https://doi.org/10.70066/jahm.v13i5.1873Keywords:
Lung cancer, quinovic acid, network pharmacology, molecular docking, PI3K-AKT, BRAFAbstract
Background: Lung cancer is the predominant cause of cancer-related death globally, attributed to delayed diagnosis and limited therapeutic effectiveness. Natural chemicals provide potential avenues for the development of innovative cancer therapeutics. Objective: This study seeks to investigate the anticancer efficacy of quinovic acid in lung cancer via a network pharmacology approach combined with molecular docking techniques. Methods: A network pharmacology analysis was conducted to discover the proteins targeted by Quinovic acid. The targets were also analysed for potential overlap with genes linked to lung cancer. A Protein-Protein Interaction (PPI) network was constructed to identify pivotal hub genes. Molecular docking simulations were conducted to evaluate the binding affinity of quinovic acid with the indicated targets. Results: Network pharmacology indicates that quinovic acid interacts with a diverse array of proteins, predominantly phosphatases (33.3%) and phosphodiesterases (26.7%). A substantial overlap of 49 genes was identified between quinovic acid targets and lung cancer-associated genes, suggesting potential therapeutic relevance. PPI analysis identified essential hub genes including TP53, EGFR, KRAS, BRAF, and PIK3CA, which are involved in significant signalling pathways such as PI3K-AKT, MAPK, and apoptosis. Computer-simulated ligand binding analyses demonstrated substantial binding affinities of quinovic acid, particularly with BRAF and PIK3CA (-9.2 kcal/mol). Conclusion: The results indicate that quinovic acid may inhibit cancer proliferation by altering many critical oncogenic pathways, rendering it a promising option for lung cancer treatment. Additional experimental validation is necessary to demonstrate its therapeutic effectiveness.
References
Thandra, K. C., Barsouk, A., Saginala, K., Aluru, J. S., & Barsouk, A. (2021). Epidemiology of lung cancer. Contemporary oncology (Poznan, Poland), 25(1), 45–52. https://doi.org/10.5114/wo.2021.103829
El-Hussein, A., Manoto, S. L., Ombinda-Lemboumba, S., Alrowaili, Z. A., & Mthunzi-Kufa, P. (2021). A Review of Chemotherapy and Photodynamic Therapy for Lung Cancer Treatment. Anti-cancer agents in medicinal chemistry, 21(2), 149–161. https://doi.org/10.2174/1871520620666200403144945
Lau, S. C. M., Pan, Y., Velcheti, V., & Wong, K. K. (2022). Squamous cell lung cancer: Current landscape and future therapeutic options. Cancer cell, 40(11), 1279–1293. https://doi.org/10.1016/j.ccell.2022.09.018
Asma, S. T., Acaroz, U., Imre, K., Morar, A., Shah, S. R. A., Hussain, S. Z., Arslan-Acaroz, D., Demirbas, H., Hajrulai-Musliu, Z., Istanbullugil, F. R., Soleimanzadeh, A., Morozov, D., Zhu, K., Herman, V., Ayad, A., Athanassiou, C., & Ince, S. (2022). Natural Products/Bioactive Compounds as a Source of Anticancer Drugs. Cancers, 14(24), 6203. https://doi.org/10.3390/cancers14246203
Naeem, A., Hu, P., Yang, M., Zhang, J., Liu, Y., Zhu, W., & Zheng, Q. (2022). Natural Products as Anticancer Agents: Current Status and Future Perspectives. Molecules (Basel, Switzerland), 27(23), 8367. https://doi.org/10.3390/molecules27238367
Mostafa, M., Nahar, N., Mosihuzzaman, M., Sokeng, S. D., Fatima, N., Atta-Ur-Rahman, & Choudhary, M. I. (2006). Phosphodiesterase-I inhibitor quinovic acid glycosides from Bridelia ndellensis. Natural product research, 20(7), 686–692. https://doi.org/10.1080/14786410600661658
Akesson, C., Lindgren, H., Pero, R. W., Leanderson, T., & Ivars, F. (2003). An extract of Uncaria tomentosa inhibiting cell division and NF-kappa B activity without inducing cell death. International immunopharmacology, 3(13-14), 1889–1900. https://doi.org/10.1016/j.intimp.2003.07.001
Saleem, S., Jafri, L., ul Haq, I., Chang, L. C., Calderwood, D., Green, B. D., & Mirza, B. (2014). Plants Fagonia cretica L. and Hedera nepalensis K. Koch contain natural compounds with potent dipeptidyl peptidase-4 (DPP-4) inhibitory activity. Journal of ethnopharmacology, 156, 26–32. https://doi.org/10.1016/j.jep.2014.08.017
Rodak, O., Peris-Díaz, M. D., Olbromski, M., Podhorska-Okołów, M., & Dzięgiel, P. (2021). Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. Cancers, 13(18), 4705. https://doi.org/10.3390/cancers13184705
Noor, F., Asif, M., Ashfaq, U. A., Qasim, M., & Tahir Ul Qamar, M. (2023). Machine learning for synergistic network pharmacology: a comprehensive overview. Briefings in bioinformatics, 24(3), bbad120. https://doi.org/10.1093/bib/bbad120
Sasikumar, D. S. N., Thiruselvam, P., Sundararajan, V., Ravindran, R., Gunasekaran, S., Madathil, D., Kaliamurthi, S., Peslherbe, G. H., Selvaraj, G., & Sudhakaran, S. L. (2024). Insights into dietary phytochemicals targeting Parkinson's disease key genes and pathways: A network pharmacology approach. Computers in biology and medicine, 172, 108195. https://doi.org/10.1016/j.compbiomed.2024.108195
Ryntathiang I, Pooja Y, Khalid JP, Behera A, Murugesan M, Prasad M, Jothinathan MKD. (2025). Therapeutic potential of bioactive compounds from Millettia pinnata: Computational and in vitro approaches. Int Res J Multidiscip Scope. 6(1):263-273. https://doi.org/10.47857/irjms.2025.v06i01.02494
Cheng, E. S., Weber, M., Steinberg, J., & Yu, X. Q. (2021). Lung cancer risk in never-smokers: An overview of environmental and genetic factors. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 33(5), 548–562. https://doi.org/10.21147/j.issn.1000-9604.2021.05.02
International Agency for Research on Cancer. World Health Organization Lung Factsheet Globocan 2020 Available from: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf accessed on February 3, 2021
Arumugam P. (2024). Emerging role of natural product-derived phytochemicals in the green synthesis of metal nanoparticles: a paradigm shift in sustainable nanotechnology. Natural product research, 1–2. Advance online publication. https://doi.org/10.1080/14786419.2024.2432012
Singla, R. K., Kumar, R., Khan, S., Mohit, Kumari, K., & Garg, A. (2019). Natural Products: Potential Source of DPP-IV Inhibitors. Current protein & peptide science, 20(12), 1218–1225. https://doi.org/10.2174/1389203720666190502154129
Kabir, A., & Muth, A. (2022). Polypharmacology: The science of multi-targeting molecules. Pharmacological research, 176, 106055. https://doi.org/10.1016/j.phrs.2021.106055
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Manoj Kumar S
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain the copyright of their work and grant the Journal of Ayurveda and Holistic Medicine (JAHM) the right of first publication. All published articles are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) license, which permits non-commercial sharing, use, distribution, and adaptation with proper attribution and the same license terms.
JAHM ensures free, irrevocable, worldwide access to its content. Users may copy, distribute, display, and share published works for non-commercial purposes with appropriate credit to the author(s) and the journal. Limited printed copies for personal, non-commercial use are allowed under the same license.
If a submission is not accepted for publication, the author(s) will be notified.
By submitting, authors confirm that the work is original, that all listed authors have contributed and approved it, and that it does not infringe any third-party rights or duplicate work submitted elsewhere.
